Ipsen in the World

Choose your location:

Choose a Language

Contact us

Investors

As a global pharmaceutical company with a biotech mindset and a proven ability to provide new, life-changing therapies, Ipsen is a leading player in its core therapeutic areas.

Contact us

 

Craig Marks Adrien Dupin de Saint-Cyr
Vice President, Investor Relations Investor Relations Manager
+44 7584 349 193 +33 6 64 26 17 49

Contact us

YTD 2021 sales update - Webcast details

Date: Thursday 21 October 2021

Time: Conference call and webcast – 2:30pm CEST / 8:30am EST

Standard International: +44 (0) 2071 928 000

France and continental Europe: +33 (0) 1 76 70 07 94

U.K.: 08445 718 892

U.S.: (631) 510-7495

Conference ID: 4312698

Ipsen in Brief

Ipsen in Brief 2021

Discover Ipsen in two pages; our products and key figures, our objectives and our strategy.

Download

Registration document

2020 Universal Registration Document

This registration document contains forward-looking statements about Ipsen’s targets and forecasts, including the Annual Financial Report. The registration document provides a comprehensive information about the Company its activities, financial information, colleagues and legal information

Download

Capital Markets Day

Capital Markets Day

Stock information

Share price and stock information, benchmark, orders, transactions: find out Ipsen share-related data.

Ipsen shares
ADR program Shareholding structure Analyst coverage

ADR program

Ipsen established a sponsored level I American Depository Receipt (ADR) program in the United States in June 2010 with Deutsche Bank trust company Americas (Deutsche Bank).

  • Ticker: IPSEY
  • Structure: Sponsored Level I ADR
  • Exchange: OTC
  • Ratio (ORD:ADR): 1:4
  • ADR ISIN: US4626291060
  • ORD ISIN: FR0010259150

CONTACT DETAILS FOR ADR HOLDERS:

Deutsche Bank Shareholder Services
AST
Operations Center
6201 15th Avenue
Brooklyn, NY 11219
USA

Email:
Toll-free number: +1 (866) 706-0509
Direct Dial: +1 (718) 921-8137

The Company’s ADR program is sponsored by Deutsche Bank. As the depository bank Deutsche Bank performs the following roles for ADR holders:

  • Records and maintains the register of ADR holders
  • Is the stock transfer agent
  • Distributes dividends in U.S. dollars (if applicable)
  • Facilitates the proxy voting process and exercises the voting rights on behalf of ADR holders (if applicable)
  • Issues and cancels Ipsen ADSs (American Depository Shares)
  • Can distribute company circulars and Annual General Meeting documentation (if applicable)

For those holders who are not registered because their shares are held through a ‘Street name’ (nominee account), your nominee will receive company documents from time to time from Deutsche Bank to distribute to ADR holders. You need to make arrangements with your nominee if you wish to receive such documents and to be able to exercise your vote through the depositary bank at general meetings (if applicable).

Shareholding structure

Shareholder structure

Analyst coverage

Stock information

Research & Development pipeline

Ipsen R&D has a valuable pipeline encompassing both lifecycle management of our well-established products, and the development of innovative new molecules.

Learn more

We are focused on accelerating our sales growth while improving our profitability and cash flow generation, in order to further invest in business development to build an innovative and sustainable pipeline and to maintain the growth momentum of the business.


Aymeric Le Chatelier, CFO

Financial objectives and outlook

a

2021 financial objectives Mid-term financial outlook and capital-allocation strategy

2021 financial objectives

The Company upgraded its financial guidance for FY 2021 on 21 Ocotber 2021, based on the strong performance in the year to date, the gradual easing of the COVID-19 pandemic and a limited impact from the launch of generic lanreotide in Europe.

Total sales growth – greater than 11.0%, at constant exchange rates

Core operating margin – around 34%, excluding any potential impact of incremental investments from external innovation

Mid-term financial outlook and capital-allocation strategy

Ipsen provided its financial outlook for the period 2020-2024:

  • Total sales CAGR between +2% and +5%, assuming potential additional indications
  • Commitment to invest in R&D, supported by SG&A efficiencies
    • Lower SG&A costs as a percentage of total sales driven by further focus and optimization
    • Higher R&D costs as a percentage of total sales driven by external innovation strategy

External innovation is Ipsen’s number one priority for capital allocation. In support of its external-innovation strategy, Ipsen expects to generate by 2024 a cumulative €3bn of firepower for pipeline expansion, excluding the sale of any assets.

Financial objectives

Annual Report 2020

Under the overarching theme of Focus. Together. For patients & society, Ipsen will be focusing on four strategic priorities to accelerate our innovation and drive positive impact for patients, employees, shareholders and society – a strategy for the short and long term.

Annual Report

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2021